Cold Genesys, Inc. is a clinical-stage immuno-oncology company focused on the development of oncolytic immunotherapies to combat cancer. In 2010, Cold Genesys acquired exclusive worldwide rights to develop CG0070 from BioSante Pharmaceuticals. CG0070 is currently under investigation in a Phase II, single-arm, open-label, pivotal study (BOND II) for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who have failed BCG therapy and refused cystectomy. In addition, Cold Genesys is exploring the use of CG0070 in combination with immune checkpoint modulators in different solid tumors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/06/15 | $10,000,000 | Series B |
Ally Bridge Group Song Hong Fang Whitesun Healthcare Ventures WI Harper Group | undisclosed |
| 03/18/19 | $22,000,000 | Series C |
ORI Healthcare Fund Perseverance Capital Management | undisclosed |
